20.500.12556/DiRROS-27793 A three-dose mRNA COVID-19 vaccine regime produces both suitable immunogenicity and satisfactory efficacy in patients with solid cancers Background: The recommended booster third dose of vaccination against COVID-19 in cancer patients seems reasonable to protect them against a severe disease course. A prospective study was designed to assess the immunogenicity, efficacy, and safety of COVID-19 vaccination in this cohort. Methods: Patients with solid malignancies on active treatment were followed up after the primary course and booster third dose of vaccination to assess their anti-SARS-CoV-2 S1 IgG levels, efficacy in the case of SARS-CoV-2 infection, and safety. Results: Out of 125 patients receiving the primary course of vaccination, 66 patients received a booster third dose of mRNA vaccine, with a 20-fold increase in median anti-SARS-CoV-2 S1 IgG levels compared to Ab levels six months post-primary course of vaccination (p < 0.0001). After the booster third dose, anti-SARS-CoV-2 S1 IgG levels were comparable to healthy controls (p = 0.113). There was a decline in Ab levels 3 (p = 0.0003) and 6 months (p < 0.0001) post-third booster dose. No patients had either a severe disease course or a lethal outcome in the case of SARS-CoV-2 infection after the third booster dose. Conclusion: The third booster vaccination dose against COVID-19 in solid cancer patients triggers substantial immunogenicity and is safe and effective for preventing a severe COVID-19 disease course. solid cancer COVID-19 vaccination booster third dose čvrsti tumorji cepljenje proti Covid-19 poživitveni odmerek true false true MDPI AG, 2013- Vaccines Angleški jezik Slovenski jezik © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Neznano 2026-02-25 09:09:18 2026-02-25 09:09:18 2026-02-26 03:55:11 0000-00-00 00:00:00 2023 0 0 Nasl. z nasl. zaslona; Opis vira z dne 24. 5. 2023; Str. 1-12 iss. 6 Vol. 11 2023 0000-00-00 Zaloznikova Objavljeno apc 2023-04-01 2023-05-22 2023-05-23 616-006 2076-393X 10.3390/vaccines11061017 153238275 https://www.mdpi.com/2076-393X/11/6/1017 1 4948e426-1221-11f1-9cb0-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=40861 RAZ_Janzic_Urska_2023.pdf RAZ_Janzic_Urska_2023.pdf 1 40ACF11CB9D3946987B74CDC42E116B1 d567a2de7797371e5e6574bd822b32e8b648262615ee5d804338701bd955601a 476f717a-1222-11f1-9cb0-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=40862 Univerzitetna klinika za pljučne bolezni in alergijo Golnik 0 0 0